E. Alexander

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab.

P. Pang, A. Cathcart, E. Mogalian, 2021, The New England journal of medicine.

Intramuscular Versus Intravenous SARS-CoV-2 Neutralizing Antibody Sotrovimab for Treatment of COVID-19 (COMET-TAIL): A Randomized Non-inferiority Clinical Trial

A. Nader, E. Mogalian, P. Pang, 2023, medRxiv.

Safety, Virology, Pharmacokinetics, and Clinical Experience of High-dose Intravenous Sotrovimab for the Treatment of Mild to Moderate COVID-19: An Open-label Clinical Trial

A. Skingsley, C. Xu, G. Schnell, 2023, medRxiv.

Population pharmacokinetics and exposure‐response analysis of a single dose of sotrovimab in the early treatment of patients with mild to moderate COVID‐19

A. Nader, E. Mogalian, J. Passarell, 2023, CPT: pharmacometrics & systems pharmacology.

Antibody therapy reverses biological signatures of COVID-19 progression

A. Telenti, L. Purcell, M. C. Maher, 2021, Cell Reports Medicine.